Alumis Inc. (ALMS) Investor Relations Documents

Alumis Inc. (ALMS) investor relations documents from the company's IR site: 5 presentations, 35 press releases; latest deck 2026-08-14. Read in-app with summaries. First-party data.

Alumis Corporate Presentation - August 2026: Alumis' Envudeucitinib shows strong Phase 3 psoriasis results, targeting a $40B market with an NDA filing expected Q4 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14PresentationAlumis Corporate Presentation - August 2026
2026-08-13Press releaseAlumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
2026-08-10Press releasePDF Version
2026-08-10Press releaseEnvudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Report
2026-05-14Press releaseAlumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
2026-03-30PresentationEnvudeucitinib ONWARD1 and ONWARD2 Phase 3 Data Presentation
2026-03-28Press releasePDF Version
2026-03-28Press releaseAlumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms
2026-06-06PresentationPDF Version
2026-03-19Press releaseAlumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
2026-06-06PresentationPDF Version
2026-03-18Press releaseAlumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasi
2026-03-02Press releasePDF Version
2026-03-02Press releaseAlumis to Present at the Leerink Partners Global Healthcare Conference
2026-02-05Press releaseAlumis to Participate in Upcoming February Investor Conferences
2026-01-09Press releasePDF Version
2026-01-09Press releaseAlumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Sha
2026-01-07Press releasePDF Version
2026-01-07Press releaseAlumis Announces Pricing of Upsized Public Offering of Common Stock
2026-01-06Earnings deckAlumis Envudeucitinib ONWARD Phase 3 Plaque Psoriasis Trial Results Event Presentation
2026-01-06Press releasePDF Version
2026-01-06Press releasePDF Version
2026-01-06Press releaseAlumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3
2026-01-06Press releaseAlumis Announces Proposed Public Offering of Common Stock
2026-01-05Press releasePDF Version
2026-01-05Press releaseAlumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Sever
2025-11-04Press releasePDF Version
2025-11-04Press releaseAlumis to Participate in Upcoming November Investor Conferences
2025-08-29Press releasePDF Version
2025-08-13Press releasePDF Version
2025-07-24Press releasePDF Version
2025-07-24Press releaseAlumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor
2025-05-29Press releasePDF Version
2025-05-29Press releasePDF Version
2025-05-29Press releaseAlumis to Present at the Jefferies Global Healthcare Investor Conference
2025-05-29Press releaseAlumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Ne
2025-05-21Press releasePDF Version
2025-05-21Press releaseAlumis Completes Merger with ACELYRIN
2025-05-13Press releasePDF Version
2025-05-13Press releaseAlumis Stockholders Approve Merger with ACELYRIN

ALMS overview · ALMS earnings · ALMS financials · ALMS KPIs · ALMS documents · ALMS ownership · ALMS peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.